Recombinant human erythropoietin - Center of Molecular Immunology

Drug Profile

Recombinant human erythropoietin - Center of Molecular Immunology

Alternative Names: iorEPOCIM; NeuroEPO (nasal); NeuroEPO - Center of Molecular Immunology

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Center of Molecular Immunology
  • Class Antianaemics; Erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia
  • Phase II Cardiovascular disorders
  • Phase I/II Cerebral infarction

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 21 Jan 2016 Phase-I/II clinical trials in Cerebral infarction in Cuba (Intranasal)
  • 01 Jun 2014 Withdrawn for Anaemia in Brazil (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top